EP1366061A4 - Verfahren zur behandlung von beta-amyloid-precursor-erkrankungen - Google Patents

Verfahren zur behandlung von beta-amyloid-precursor-erkrankungen

Info

Publication number
EP1366061A4
EP1366061A4 EP02718903A EP02718903A EP1366061A4 EP 1366061 A4 EP1366061 A4 EP 1366061A4 EP 02718903 A EP02718903 A EP 02718903A EP 02718903 A EP02718903 A EP 02718903A EP 1366061 A4 EP1366061 A4 EP 1366061A4
Authority
EP
European Patent Office
Prior art keywords
maturation
amyloid beta
disorders
protein precursor
beta protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02718903A
Other languages
English (en)
French (fr)
Other versions
EP1366061A2 (de
Inventor
Lawrence Friedhoff
Joseph Buxbaum
Edward I Cullen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Corp
Original Assignee
Andrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Corp filed Critical Andrx Corp
Publication of EP1366061A2 publication Critical patent/EP1366061A2/de
Publication of EP1366061A4 publication Critical patent/EP1366061A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02718903A 2001-02-05 2002-02-05 Verfahren zur behandlung von beta-amyloid-precursor-erkrankungen Withdrawn EP1366061A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26588601P 2001-02-05 2001-02-05
US265886P 2001-02-05
PCT/US2002/003256 WO2002062824A2 (en) 2001-02-05 2002-02-05 Method of treating amyloid ? precursor disorder

Publications (2)

Publication Number Publication Date
EP1366061A2 EP1366061A2 (de) 2003-12-03
EP1366061A4 true EP1366061A4 (de) 2006-04-26

Family

ID=23012272

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02718903A Withdrawn EP1366061A4 (de) 2001-02-05 2002-02-05 Verfahren zur behandlung von beta-amyloid-precursor-erkrankungen

Country Status (3)

Country Link
EP (1) EP1366061A4 (de)
CA (1) CA2437480A1 (de)
WO (1) WO2002062824A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
WO2003000381A1 (en) 2001-06-25 2003-01-03 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
JP2007527387A (ja) 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
EP1702626B1 (de) 2003-12-30 2011-11-30 Kowa Company, Ltd. Screening-verfahren fuer gamma-sekretase-inhibitoren
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
JP7550448B2 (ja) 2017-11-22 2024-09-13 エイチディーエル セラピューティクス インコーポレイテッド 血漿処理システムの流体回路をプライミングするシステムおよび方法
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006470A1 (en) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
EP0783104A1 (de) * 1995-12-27 1997-07-09 Oriental Yeast Co., Ltd. Test für lössliches amyloid Vorläuferprotein
WO1997048391A2 (en) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
WO1998013488A2 (en) * 1996-09-24 1998-04-02 Schering Aktiengesellschaft Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease
WO1998019169A1 (en) * 1996-10-31 1998-05-07 Trustees Of Boston University Diagnostic method for the detection of alzheimer's disease in living patients
WO1999021978A1 (en) * 1997-10-28 1999-05-06 The Miriam Hospital, A Lifespan Partner Non-transgenic animal model of alzheimer's disease
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease
WO1999048488A2 (en) * 1998-03-23 1999-09-30 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
WO2000028981A2 (en) * 1998-11-13 2000-05-25 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor
WO2000031548A1 (en) * 1998-11-25 2000-06-02 Scios Inc. Prevention and treatment of amyloid-associated disorders
WO2001032161A2 (en) * 1999-11-04 2001-05-10 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006470A1 (en) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
EP0783104A1 (de) * 1995-12-27 1997-07-09 Oriental Yeast Co., Ltd. Test für lössliches amyloid Vorläuferprotein
WO1997048391A2 (en) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
WO1998013488A2 (en) * 1996-09-24 1998-04-02 Schering Aktiengesellschaft Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease
WO1998019169A1 (en) * 1996-10-31 1998-05-07 Trustees Of Boston University Diagnostic method for the detection of alzheimer's disease in living patients
WO1999021978A1 (en) * 1997-10-28 1999-05-06 The Miriam Hospital, A Lifespan Partner Non-transgenic animal model of alzheimer's disease
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease
WO1999048488A2 (en) * 1998-03-23 1999-09-30 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
WO2000028981A2 (en) * 1998-11-13 2000-05-25 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor
WO2000031548A1 (en) * 1998-11-25 2000-06-02 Scios Inc. Prevention and treatment of amyloid-associated disorders
WO2001032161A2 (en) * 1999-11-04 2001-05-10 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, YANG L B ET AL: "Amyloid beta peptide (Abeta) induced TNF-alpha release from Alzheimer microglia is inhibited by diclofenac, an anti-inflammatory drug", XP002369758, Database accession no. PREV200100121209 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, WESTERMAN M A ET AL: "Ibuprofen as a treatment of cognitive decline in the Tg2576 mouse model of Alzheimer's disease", XP002369757, Database accession no. PREV200100563487 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1998, NETLAND E E ET AL: "Indomethacin reverses the microglial response to amyloid [beta]-protein", XP002369759, Database accession no. EMB-1998240403 *
DOVEY H F ET AL: "FUNCTIONAL GAMMA-SECRETASE INHIBITORS REDUCE BETA-AMYLOID PEPTIDE LEVELS IN BRAIN", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 76, no. 1, January 2001 (2001-01-01), pages 173 - 181, XP001147446, ISSN: 0022-3042 *
NEUROBIOLOGY OF AGING 1998 UNITED STATES, vol. 19, no. 3, 1998, pages 201 - 204, ISSN: 0197-4580 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30TH ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 04-09, 2000, pages Abstract No. - 763.13, ISSN: 0190-5295 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, 31ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 10-15, 2001, pages 1718, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
CA2437480A1 (en) 2002-08-15
WO2002062824A3 (en) 2002-11-21
WO2002062824A2 (en) 2002-08-15
EP1366061A2 (de) 2003-12-03

Similar Documents

Publication Publication Date Title
EP1511508A4 (de) Verfahren zur behandlung dyslipidämischer störungen
DE60233414D1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
EP1434801A4 (de) Behandlung von störungen des zentralen nervensystems
EP1558081A4 (de) Verfahren zur behandlung von funktionalen darmerkrankungen
DZ3500A1 (fr) Derives de phenethanolamine pour le traitement de maladies respiratoires
DE69918222D1 (de) Intranasale Zubereitungen zur Behandlung sexueller Störungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
EP1809286A4 (de) Verfahren zur behandlung von bewegungsstörungen
EP1578988A4 (de) Tnf-alpha-varianten auf proteinbasis zur behandlung von erkrankungen in verbindung mit tnf-alpha
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
ATE522229T1 (de) Anti-ngf-antikörper zur behandlung verschiedener erkrankungen
ATE344027T1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
EP1463481A4 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen des zentralen nervensystems
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
EP1677816A4 (de) Therapeutisches verfahren
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
EP1461122A4 (de) Behandlung von erkrankungen des urogenitalsystems
EP1389105A4 (de) Behandlungsverfahren
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
EP1494696A4 (de) Behandlung von lungenerkrankungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030903

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RTI1 Title (correction)

Free format text: METHOD OF TREATING AMYLOID BETA PRECURSOR DISORDERS

A4 Supplementary search report drawn up and despatched

Effective date: 20060314

17Q First examination report despatched

Effective date: 20061031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070904